MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• MoonLake Immunotherapeutics (NASDAQ:MLTX) has received a consensus recommendation of "Moderate Buy" from nine brokerages, with seven analysts issuing buy recommendations and two recommending a hold.
• The average one-year price target for the stock is $73.14, with several analysts setting targets in the range of $65.00 to $80.00.
• Approximately 93.85% of MoonLake Immunotherapeutics' shares are currently held by institutional investors, reflecting strong institutional interest in the company.

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $73.14.

Several research firms have recently issued reports on MLTX. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a research note on Monday, July 28th. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $67.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Wedbush reissued an "outperform" rating and issued a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Finally, Wolfe Research raised shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a research note on Monday, May 19th.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX traded up $2.48 on Thursday, reaching $52.92. The company's stock had a trading volume of 957,582 shares, compared to its average volume of 509,369. The company has a 50-day simple moving average of $47.46 and a 200 day simple moving average of $42.85. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $58.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 21.11 and a current ratio of 21.11. The company has a market cap of $3.39 billion, a P/E ratio of -23.01 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.13. During the same quarter in the prior year, the company posted ($0.22) earnings per share. As a group, equities research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its holdings in shares of MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after purchasing an additional 338 shares during the period. US Bancorp DE raised its holdings in shares of MoonLake Immunotherapeutics by 114.4% in the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after acquiring an additional 1,178 shares in the last quarter. Quarry LP purchased a new stake in MoonLake Immunotherapeutics in the first quarter worth about $94,000. Advisors Asset Management Inc. grew its holdings in MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock worth $157,000 after acquiring an additional 1,803 shares in the last quarter. Finally, Birchview Capital LP purchased a new position in MoonLake Immunotherapeutics during the 4th quarter valued at about $217,000. Hedge funds and other institutional investors own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.